氨甲环酸注射液联合丁二磺酸腺苷蛋氨酸注射剂用于肝癌手术患者的临床研究
|
摘要
目的观察氨甲环酸注射液联合丁二磺酸腺苷蛋氨酸注射剂用于肝癌手术患者的临床疗效及安全性。方法将63例拟进行肝癌手术的患者随机分为对照组30例和试验组33例。对照组于术前30 min予以丁二磺酸腺苷蛋氨酸1g,静脉注射;试验组于术前30 min予以丁二磺酸腺苷蛋氨酸1 g,静脉注射+氨甲环酸0. 75 g,静脉注射。比较2组患者的血清基质金属蛋白酶-2(MMP-2)、MMP-9和S100钙结合蛋白A4(S100A4)水平,以及药物不良反应的发生情况。结果术后24 h,试验组和对照组的MMP-2分别为(513. 56±52. 96)和(563. 74±60. 23) micrograms·L~(-1),MMP-9分别为(37. 75±2. 71)和(74. 94±5. 78) micrograms·L~(-1),S100A4分别为(52. 25±4. 95)和(73. 45±8. 44) ng·mL~(-1),差异均有统计学意义(均P <0. 05)。2组患者治疗期间均未发生明显的药物不良反应。结论氨甲环酸注射液联合丁二磺酸腺苷注射剂用于肝癌手术患者能有效地降低血清MMP-2、MMP-9和S100A4水平,且安全性较好。
Objective To observe the clinical efficacy and safety of tranexamic acid injection combined with ademetionine 1,4-butanedisulfonate injection in the treatment of patients with hepatocellular carcinoma surgery. Methods A total of 63 patients with liver cancer surgery were randomly divided into control group( n = 30 cases) and treatment group( n = 33 cases). 30 min before operation,control group was given ademetionine 1,4-butanedisulfonate injection 1 g,intravenous injection. 30 min before operation,treatment group was treated with ademetionine 1,4-butanedisulfonate injection as the control group,and tranexamic acid 0. 75 g,intravenous injection. The serum levels of matrix metalloproteinase-2( MMP-2),MMP-9 and S100 calcium binding protein A4( S100A4),and adverse drug reactions were compared between two groups. Results 24 h after operation,the main indexes of treatment and control groups were compared: MMP-2 were( 513. 56 ± 52. 96) and( 563. 74 ± 60. 23) micrograms·L~(-1),MMP-9 were( 37. 75 ± 2. 71) and( 74. 94 ± 5. 78) micrograms·L~(-1),S100A4 were( 52. 25 ± 4. 95) and( 73. 45 ± 8. 44) ng ·mL~(-1),and the differences were statistically significant( all P < 0. 05). There were no adverse drug reactions occurred during the treatment between two groups. Conclusion Tranexamic acid injection combined with ademetionine 1,4-butanedisulfonate injection can effectively reduce the serum levels of MMP-2,MMP-9 and S100A4,and the safety is high.
Objective To observe the clinical efficacy and safety of tranexamic acid injection combined with ademetionine 1,4-butanedisulfonate injection in the treatment of patients with hepatocellular carcinoma surgery. Methods A total of 63 patients with liver cancer surgery were randomly divided into control group( n = 30 cases) and treatment group( n = 33 cases). 30 min before operation,control group was given ademetionine 1,4-butanedisulfonate injection 1 g,intravenous injection. 30 min before operation,treatment group was treated with ademetionine 1,4-butanedisulfonate injection as the control group,and tranexamic acid 0. 75 g,intravenous injection. The serum levels of matrix metalloproteinase-2( MMP-2),MMP-9 and S100 calcium binding protein A4( S100A4),and adverse drug reactions were compared between two groups. Results 24 h after operation,the main indexes of treatment and control groups were compared: MMP-2 were( 513. 56 ± 52. 96) and( 563. 74 ± 60. 23) micrograms·L~(-1),MMP-9 were( 37. 75 ± 2. 71) and( 74. 94 ± 5. 78) micrograms·L~(-1),S100A4 were( 52. 25 ± 4. 95) and( 73. 45 ± 8. 44) ng ·mL~(-1),and the differences were statistically significant( all P < 0. 05). There were no adverse drug reactions occurred during the treatment between two groups. Conclusion Tranexamic acid injection combined with ademetionine 1,4-butanedisulfonate injection can effectively reduce the serum levels of MMP-2,MMP-9 and S100A4,and the safety is high.
引文
[1]张贵军,吴胜东,孙勤学,等. TACE后二期手术治疗小肝癌破裂出血的临床研究[J].肝胆胰外科杂志,2014,26(3):188-191.
[2]王叙德,刘华高,方有智,等.氨甲环酸对肝癌患者肝切除手术出血量及术后凝血功能的影响[J].中国临床药理学杂志,2017,33(23):2351-2353.
[3]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,20(11):1141-1159.
[4] LIANG J,CHEN M,HUGHES D,et al. CDK8 selectively promotes the growth of colon cancer metastases in the liver by regulating gene expression of TIMP3 and matrix metalloproteinases[J]. Cancer Res,2018,78(23):6594-6606.
[5]林名岛,林洁. S100A4基因在肿瘤中作用机制的研究进展[J].广东医学,2016,37(8):1251-1253.
[2]王叙德,刘华高,方有智,等.氨甲环酸对肝癌患者肝切除手术出血量及术后凝血功能的影响[J].中国临床药理学杂志,2017,33(23):2351-2353.
[3]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,20(11):1141-1159.
[4] LIANG J,CHEN M,HUGHES D,et al. CDK8 selectively promotes the growth of colon cancer metastases in the liver by regulating gene expression of TIMP3 and matrix metalloproteinases[J]. Cancer Res,2018,78(23):6594-6606.
[5]林名岛,林洁. S100A4基因在肿瘤中作用机制的研究进展[J].广东医学,2016,37(8):1251-1253.